XTAE
SEMG
Market cap27mUSD
Oct 09, Last price
259.80ILS
1D
-2.64%
1Q
-0.42%
Name
Seach Medical Group Ltd
Chart & performance
P/E
56.43
P/S
0.55
EPS
0.05
Div yield, %
4.65%
Shrs. gr., 5y
0.59%
Rev. gr., 5y
33.69%
Revenues
157m
-8.48%
Net income
2m
-88.73%
CFO
17m
+1.96%
Dividend
Apr 09, 202618 ILS/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Seach Medical Group Ltd is an Israeli company, established in 2002 and headquartered in Ramat Gan, that specializes in the global production and distribution of therapeutic cannabis products. Its offerings include medicinal cannabis flower (inflorescence) and various oil-based compounds, primarily marketed under the 'Nitzan' brand. The company's product line also extends to 'power powder' and 'moodpicks'.
Key people
Yogev Sarid
Chief Executive Officer, Director · since 2019
Shay Sarid
Chief Technology Officer, Director · since 2019
Amichay Rab
Vice President - Finance · since 2019
Ofir Sarid
Vice President · since 2019
Shira Sitton Dvorachek
Director of Human Resources · since 2019
Margalit Sarid
Manager of Growing Facility · since 2019
Internal Auditor · since 2015
Hagai Zachor
Business Development Manager · since 2019
Director · since 2019
Samy Backlash
Director · since 2011
Arnon Salomon
Director · since 2011
Chairman of the Board · since 2019
External Director · since 2019
External Director · since 2019
Itamar Elitzur
Independent Director · since 2019
Yossi Levi
Independent Director · since 2015
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||